{"id":60960,"date":"2024-02-28T07:18:14","date_gmt":"2024-02-28T07:18:14","guid":{"rendered":"https:\/\/medsname.com\/trinicalm-plus\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"trinicalm-plus","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fi\/product\/trinicalm-plus\/","title":{"rendered":"Trinicalm Plus"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Trinicalm Plus?<\/h3>\n
\n

Trinicalm Plus<\/strong> contains a fixed-dose combination of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> from a WHO-GMP certified manufacturer (Tripada Healthcare) — a first-generation antipsychotic<\/strong> (D2<\/sub> antagonist) paired with an anticholinergic anti-Parkinson agent<\/strong> to pre-empt the extrapyramidal side effects (EPS — parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics commonly cause. Used primarily in countries where typical antipsychotics remain in regular use for schizophrenia and severe anxiety\/agitation. Important warnings<\/strong>: trifluoperazine carries the FDA musta laatikko vanhusten dementiaan liittyv\u00e4lle kuolleisuudelle<\/strong>, plus high tardive dyskinesia and neuroleptic malignant syndrome risks; trihexyphenidyl has anticholinergic side effects (cognitive impairment, urinary retention, falls in elderly) and recognised abuse potential<\/strong> (sought for its euphoric \/ stimulant effect at supratherapeutic doses).<\/p>\n<\/div>\n

\nMit\u00e4 saat MedsBasen kautta:<\/strong> WHO-GMP sertifioitu valmistaja \u00b7 Hienotunteinen pakkaus \u00b7 Maailmanlaajuinen toimitus \u00b7 1 400+ varmennettua asiakasarviota<\/a>\n<\/div>\n

\ud83d\udce6 Jokainen tilaus on katettuna meid\u00e4n Reshipment Assurance Policy -politiikkamme piiriin<\/strong><\/a> \u2014 jos l\u00e4hetyksesi ei saavu 20 arkip\u00e4iv\u00e4ss\u00e4, l\u00e4het\u00e4mme uuden.<\/p>\n

Miksi tilata MedsBasesta<\/h3>\n

Geneeriset l\u00e4\u00e4kkeemme on hankittu WHO-GMP sertifioiduilta valmistajilta ja toimitettu maailmanlaajuisesti hienotunteisessa, neutraalissa pakkauksessa \u2014 l\u00e4\u00e4kkeen nime\u00e4 ei ole pakkauksen ulkopuolella. Korttimaksut k\u00e4sitell\u00e4\u00e4n s\u00e4\u00e4deltyjen maksunv\u00e4litt\u00e4jien kautta (tilisiirtojen kuvaukset sis\u00e4lt\u00e4v\u00e4t s\u00e4\u00e4dellyn korttimaksun k\u00e4sittelij\u00e4n \u2014 ei koskaan \u201cMedsBase\u201d tai l\u00e4\u00e4kkeen nime\u00e4). Kryptovaluutat ja SEPA-pankkisiirrot hyv\u00e4ksyt\u00e4\u00e4n my\u00f6s. Jokainen tilaus on turvattu meid\u00e4n Reshipment Assurance Policy -takuuohjelmalla.<\/p>\n<\/div>\n

T\u00e4rke\u00e4\u00e4 \u2014 t\u00e4m\u00e4 ei ole tilannekohtainen ahdistusl\u00e4\u00e4ke.<\/strong> Trinicalm Plus is a first-generation antipsychotic combined with an anticholinergic anti-Parkinson agent<\/strong>, joka m\u00e4\u00e4r\u00e4t\u00e4\u00e4n ja annostellaan viikkojen aikana schizophrenia and other psychotic disorders, severe anxiety \/ agitation in some legacy regimens, with prophylactic coverage of antipsychotic-induced extrapyramidal symptoms (EPS)<\/strong>. Se on ei<\/strong> oikea l\u00e4\u00e4ke akuuttiin, suorituskykyyn liittyv\u00e4\u00e4n ahdistukseen (lent\u00e4minen, julkiset puheet, kokeet) \u2014 n\u00e4ihin k\u00e4ytt\u00f6tarkoituksiin beetasalpaajat (propranololi), bentsodiatsepiinit tai hydroksitsiini ovat kliinisesti sopivia. Jos sinulla ei ole diagnosoitua mielialah\u00e4iri\u00f6t\u00e4, ahdistuneisuush\u00e4iri\u00f6t\u00e4 tai psyykkist\u00e4 h\u00e4iri\u00f6t\u00e4, \u00e4l\u00e4 aloita t\u00e4t\u00e4 l\u00e4\u00e4kityst\u00e4.<\/div>\n
FDA:n musta laatikko -varoitus vanhusten dementiaan liittyv\u00e4st\u00e4 kuolleisuudesta.<\/strong> Kaikki antipsykootit (ep\u00e4tyypilliset ja perinteiset) sis\u00e4lt\u00e4v\u00e4t FDA:n mustan laatikon varoituksen kohonneesta kuolleisuudesta, kun niit\u00e4 k\u00e4ytet\u00e4\u00e4n dementiaan liittyv\u00e4n psykoottisten tai k\u00e4ytt\u00e4ytymish\u00e4iri\u00f6iden hoitoon vanhuksilla. T\u00e4m\u00e4 l\u00e4\u00e4ke on ei hyv\u00e4ksytty<\/strong> dementiaan liittyvien oireiden hoitoon.<\/div>\n

What Is Trinicalm Plus?<\/h2>\n

Trinicalm Plus is an oral tablet of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> in fixed-dose combination, manufactured by Tripada Healthcare. The combination addresses a long-standing problem with first-generation antipsychotics: high-potency D2<\/sub> antagonists like trifluoperazine routinely cause extrapyramidal side effects (drug-induced parkinsonism, akathisia, acute dystonia) that limit tolerability and adherence. Co-prescribing an anticholinergic anti-Parkinson agent like trihexyphenidyl mitigates these motor side effects.<\/p>\n

This is a second-line approach in modern psychiatry<\/strong> — first-line is to use an atypical antipsychotic (which has lower EPS risk and does not require routine anticholinergic cover). The combination remains common in countries where typical antipsychotics are first-line for cost or availability reasons.<\/p>\n

Component Drugs<\/h2>\n

What each component does<\/h2>\n\n\n\n\n\n\n
Komponentti<\/th>\nLuokka<\/th>\nToimintamekanismi<\/th>\nRole in this combination<\/th>\n<\/tr>\n<\/thead>\n
Trifluoperazine 5 mg<\/td>\nFirst-generation phenothiazine antipsychotic (high-potency)<\/td>\nTight D2<\/sub> antagonism in mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways<\/td>\nPrimary antipsychotic action; also approved for short-term treatment of severe non-psychotic anxiety not responsive to usual measures (legacy indication)<\/td>\n<\/tr>\n
Trihexyphenidyl 2 mg<\/td>\nCentrally-acting anticholinergic anti-Parkinson agent<\/td>\nM1 muscarinic antagonism in the basal ganglia, restoring acetylcholine \/ dopamine balance<\/td>\nPre-empts and treats trifluoperazine-induced parkinsonism, dystonia, and akathisia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Hyv\u00e4ksytyt k\u00e4ytt\u00f6aiheet<\/h2>\n
    \n
  • Schizophrenia and other psychotic disorders<\/strong> requiring trifluoperazine therapy with prophylactic EPS coverage<\/li>\n
  • Severe anxiety \/ agitation<\/strong> not responsive to standard treatment (legacy trifluoperazine indication; first-line modern alternatives are SSRIs and atypical antipsychotics)<\/li>\n<\/ul>\n

    Annostus<\/h2>\n\n\n\n\n\n\n\n
    K\u00e4ytt\u00f6aihe<\/th>\nTyypillinen annos<\/th>\nEnimm\u00e4ism\u00e4\u00e4r\u00e4<\/th>\nHuomautuksia<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia \/ psychosis<\/td>\n1 tablet (5\/2) BID–TID<\/td>\n3 tablets (15 mg trifluoperazine + 6 mg trihexyphenidyl) per day<\/td>\nTrifluoperazine total 5–15 mg\/day in fixed combination; higher trifluoperazine doses require separate dosing<\/td>\n<\/tr>\n
    Severe anxiety<\/td>\n1 tablet BID<\/td>\n2 tablets\/day<\/td>\nShort-term only — weeks rather than months; reassess for switch to SSRI \/ SNRI<\/td>\n<\/tr>\n
    I\u00e4kk\u00e4\u00e4t<\/td>\n½ tablet BID if combination is unavoidable<\/td>\n\u2014<\/td>\nHigh EPS, anticholinergic, and falls risk; black-box dementia warning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Side Effects (by Component)<\/h2>\n

    Trifluoperazine side effects<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
    Toimintamekanismi<\/th>\nVaikutukset<\/th>\nHuomautuksia<\/th>\n<\/tr>\n<\/thead>\n
    D2<\/sub> blockade (nigrostriatal)<\/td>\nAcute dystonia (eye-rolling, torticollis, jaw clenching), parkinsonism (tremor, rigidity, bradykinesia), akathisia (inner restlessness), tardive dyskinesia (long-term involuntary movements)<\/td>\nHigh risk — the reason trihexyphenidyl is co-prescribed; tardive dyskinesia can be irreversible and develops with long-term exposure<\/td>\n<\/tr>\n
    D2<\/sub> blockade (tuberoinfundibular)<\/td>\nHyperprolactinaemia (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction)<\/td>\nCommon with high-potency typicals<\/td>\n<\/tr>\n
    H1<\/sub> salpaus<\/td>\nSedaatio<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    Alfa-1-salpaus<\/td>\nOrtostaattinen hypotensio<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    QT-ajan piteneminen<\/td>\nCardiac arrhythmia risk<\/td>\nPerus-EKG; varovaisuus muiden QT-aikaa pident\u00e4vien l\u00e4\u00e4kkeiden kanssa<\/td>\n<\/tr>\n
    Muu<\/td>\nPhotosensitivity, ocular changes, jaundice<\/td>\nPitk\u00e4n aikav\u00e4lin huolenaiheet<\/td>\n<\/tr>\n
    Harvinainen mutta vakava<\/td>\nNeuroleptic malignant syndrome (hyperthermia, rigidity, autonomic instability, altered mental status)<\/td>\nMedical emergency<\/td>\n<\/tr>\n
    Harvinainen<\/td>\nLowered seizure threshold<\/td>\nCaution in epilepsy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Trihexyphenidyl side effects<\/h2>\n\n\n\n\n\n\n\n\n
    Toimintamekanismi<\/th>\nVaikutukset<\/th>\nHuomautuksia<\/th>\n<\/tr>\n<\/thead>\n
    Peripheral anticholinergic<\/td>\nDry mouth, blurred vision, constipation, urinary retention<\/td>\nCommon; particularly problematic with BPH<\/td>\n<\/tr>\n
    Central anticholinergic<\/td>\nConfusion, memory impairment, cognitive dulling, agitation<\/td>\nOlder adults at greatest risk — linked to long-term cognitive decline<\/td>\n<\/tr>\n
    Muu<\/td>\nTachycardia, dizziness, falls<\/td>\nFalls risk in elderly<\/td>\n<\/tr>\n
    T\u00e4rke\u00e4\u00e4<\/td>\nAbuse potential<\/strong><\/td>\nTrihexyphenidyl is sought at supratherapeutic doses for euphoric \/ stimulant \/ hallucinogenic effects; some jurisdictions have introduced controls. Patients with substance use history need monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    L\u00e4\u00e4keaineenvaihdunta<\/h2>\n

    QT-ajan piteneminen<\/strong>: avoid combination with other QT-prolonging drugs — ziprasidone, citalopram (high dose), methadone, ondansetron, fluoroquinolones.<\/p>\n

    Anticholinergic stacking<\/strong>: trihexyphenidyl already pushes anticholinergic burden — combine cautiously with TCAs, paroxetine, antihistamines, oxybutynin, hyoscyamine; in older adults this can produce confusion, falls, and urinary retention.<\/p>\n

    CNS depression<\/strong>: alcohol, benzodiazepines, opioids — additive sedation.<\/p>\n

    Verenpainel\u00e4\u00e4kkeet<\/strong>: additiivinen ortostaattinen hypotensio.<\/p>\n

    Levodopa antagonism<\/strong>: trifluoperazine D2<\/sub> blockade reduces levodopa effect — problematic in Parkinson’s disease.<\/p>\n

    Why Modern Practice Often Avoids This Combination<\/h2>\n

    Where atypical antipsychotics are available and affordable, modern practice generally avoids first-generation antipsychotics + routine anticholinergic cover<\/strong> because:<\/p>\n